Licenses and Supply Agreements (Tables)

12 Months Ended

Dec. 31, 2023

Licenses And Supply Agreements

Schedule of Royalty Rate

Annual Sales of Royalty Qualifying Licensed Products	Royalty Rate
<$500,000,000		2	%
500,000,000 to < $1,000,000,000		4	%
> $1,000,000,000)		6	%

Annual Sales of Royalty Qualifying Licensed Products	Royalty Rate
<$500,000,000		2	%
500,000,000 to < $1,000,000,000		4	%
> $1,000,000,000)		6	%

 

Schedule of Consideration

Consideration for License to Cytocom as of December 31, 2022

Consideration / Assumption of:
Notes and associated accrued interest in default	$	3,302,209
Accounts payable and accruals		230,000
Past Due Employee Obligations		1,110,567
Total anticipated Consideration	$	4,642,776
Recognized through December 31, 2020		(3,302,209	)
To Be Recognized upon Execution	$	1,340,567